Ascentage Pharma Group International
Research Ascentage Pharma Group International (AAPG) on Bullrun: market cap USD 1.57B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAAPG
- ExchangeNASDAQ
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.57B
- Financial periodQ4 2025
Valuation Snapshot
latest market cap is USD 1.57B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | CNY 980.65M | -CNY 405.43M | n/a | n/a | n/a | CNY 1.24B | CNY 1.67B | CNY 264.19M |
| FY2023 | CNY 221.98M | -CNY 925.64M | n/a | n/a | n/a | CNY 1.07B | CNY 1.80B | CNY 60.42M |
| FY2022 | CNY 209.71M | -CNY 882.92M | n/a | n/a | n/a | n/a | n/a | n/a |
| FY2021 | CNY 27.91M | -CNY 782.42M | n/a | n/a | n/a | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.57B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.45B | n/a | n/a | n/a |
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ascentage Pharma Group International's market cap?
Ascentage Pharma Group International's market capitalization is USD 1.57B.
What does Ascentage Pharma Group International do?
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.